TITLE

The role of morphine glucuronides in cancer pain

AUTHOR(S)
Mercadante, S.
PUB. DATE
March 1999
SOURCE
Palliative Medicine;1999, Vol. 13 Issue 2, p95
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Morphine metabolites are involved in various ways in determining the complex effects of morphine, both favourable and adverse, and may complicate the clinical use of morphine in the treatment of cancer pain. The production and effects of the principal morphine metabolites, morphine-3-glucuronide and morphine-6-glucuronide, in both normal and pathological states have been reviewed in the current literature. Therapeutic implications are also reviewed on the basis of experimental and clinical reports. The presence of these metabolites should be recognized in the chronic treatment of cancer pain with morphine, especially in the presence of renal impairment, and should be considered to have an important influence on opioid responsiveness, defined as a balance between the achievement of an optimal analgesia and the occurrence of adverse effects.
ACCESSION #
1774133

 

Related Articles

  • A Patient Preference Study Comparing Two Extended-Release Morphine Sulfate Formulations (Once-Daily Kadian versus Twice-Daily MS Contin) for Cancer Pain. Kerr, R.O.; Tester, W.J. // Clinical Drug Investigation;2000, Vol. 19 Issue 1, p25 

    Objective: To compare pain control, patient preference and tolerability for two extended-release formulations of morphine sulfate, Kadian capsules (administered once daily) and MS Contin tablets (administered twice daily), in the treatment of chronic cancer pain. Patients and Methods: A...

  • Morphine: The benefits are worth the risks. Brown, Susan J. // RN;Mar87, Vol. 50 Issue 3, p20 

    Presents guidelines on the use of morphine to control pain in cancer patients. Mechanism of action of morphine; Manner by which morphine can be administered effectively; Effect of delays in administration. INSET: My wish for Willie.

  • Morphine, constipation and performance status in advanced cancer patients. Fallon, M.T. // Palliative Medicine;1999, Vol. 13 Issue 2, p159 

    Studies constipation associated with the use of morphine in treatment of pain caused by advanced cancer. Characteristics of cancer patients included in the study; Conflict between data from the study and beliefs about morphine-caused constipation.

  • Morphine and dryness of the mouth. White, I.D.; Hoskin, P.J.; Hanks, G.W.; Bliss, J.M. // BMJ: British Medical Journal (International Edition);5/6/89, Vol. 298 Issue 6682, p1222 

    Examines the relation between morphine sulphate and dryness of the mouth. Administration of morphine sulphate for the relief of cancer pain; Side effects of the drug; Prevalence of dryness of the mouth among cancer patients.

  • Oral narcotic mixtures. Hillier, E.R. // British Medical Journal (Clinical Research Edition);9/10/1983, Vol. 287 Issue 6394, p701 

    Examines the effectiveness of morphine and diamorphine in controlling pain of cancer patients in Great Britain. Comparison between morphine and diamorphine; Effects of morphine on blood concentrations; Use of anti-emetics in preventing nausea attacks.

  • The effects of oral morphine in "titration phase" of carcinoma pain treatment. Ljuca, Dzenita; Husic, Samir // HealthMed;Jun2010, Vol. 4 Issue 2, p434 

    The aim of the research was to establish the optimal dosage of oral morphine which would be adequate for pain control, its negative effects, frequency, intensity and the occurrence of breakthrough pain (BTP) in titration phase of severe carcinoma pain. Patients and methods. A prospective study...

  • High-Dose Morphine Is Safe Pain Control at End of Life. Miller, Karl E. // American Family Physician;2/1/2000, Vol. 61 Issue 3, p836 

    Discusses research on the use of high-dose morphine in pain control at end of life. Reference to study by M. Bercovitch, et al., from the September 1, 1999 issue of the `Cancer'; Experience of pain in patients who are facing end-of-life issues; Effectiveness of morphine in pain control;...

  • Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Lauretti, G.R.; Oliveira, G.M.; Pereira, N.L. // British Journal of Cancer;12/1/2003, Vol. 89 Issue 11, p2027 

    The antinociceptive effect of morphine and oxycodone is mediated preferentially at µ and ? receptors, respectively. The aim of this study was to evaluate the analgesic profile of the combination of morphine and oxycodone in cancer pain, compared to the standard administration of morphine...

  • Intravenous morphine for emergency treatment of cancer pain. Suresh Kumar, K.; Rajagopal, M.; Naseema, A. // Palliative Medicine;May2000, Vol. 14 Issue 3, p183 

    Despite the wide use of the World Health Organization (WHO) analgesic ladder for the relief of cancer pain, it is not uncommon to find patients presenting with severe pain to palliative care centres. This is more so in the developing world, where facilities for pain relief are few and the health...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics